{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:15:07Z","timestamp":1792818907820,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11897-025-00717-w","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:26:18Z","timestamp":1761121578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor\u2013Myocarditis: Diagnostic and Prognostic Evidence and Limitations"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-3307","authenticated-orcid":false,"given":"Joe-Elie","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Baldassarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Redheuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Boussouar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paaladinesh","family":"Thavendiranathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Procureur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"717_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/annurev-pharmtox-022820-093805","volume":"61","author":"A Geraud","year":"2021","unstructured":"Geraud A, Gougis P, Vozy A, et al. Clinical pharmacology and interplay of immune checkpoint agents: a Yin-Yang balance. Annu Rev Pharmacol Toxicol. 2021;61:85\u2013112.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"717_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis P, Jochum F, Abbar B, et al. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective. eClinicalMedicine. 2024;70:102536.","journal-title":"eClinicalMedicine"},{"issue":"12","key":"717_CR3","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389.","journal-title":"Lancet Oncol"},{"key":"717_CR4","doi-asserted-by":"crossref","unstructured":"Salem JE, Ajrouche A, Rozes A, Pinto S, De Rycke Y, Tubach F. Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study. Eur Heart J. 2025.","DOI":"10.1093\/eurheartj\/ehaf682"},{"issue":"5","key":"717_CR5","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"JE Salem","year":"2023","unstructured":"Salem JE, Bretagne M, Abbar B, et al. Abatacept\/Ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023;13(5):1100\u201315.","journal-title":"Cancer Discov"},{"issue":"12","key":"717_CR6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138.","journal-title":"JAMA Oncol"},{"key":"717_CR7","unstructured":"Power JR, Dolladille C, Ozbay B, et al. Immune checkpoint inhibitor-associated myocarditis: a novel risk score. Eur Heart J. 2025."},{"issue":"24","key":"717_CR8","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158\u201376.","journal-title":"J Am Coll Cardiol"},{"key":"717_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.640985","volume":"11","author":"S Ederhy","year":"2021","unstructured":"Ederhy S, Salem JE, Dercle L, et al. Role of cardiac imaging in the diagnosis of immune checkpoints inhibitors related myocarditis. Front Oncol. 2021;11:640985.","journal-title":"Front Oncol"},{"issue":"1","key":"717_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","volume":"19","author":"DR Messroghli","year":"2017","unstructured":"Messroghli DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the society for cardiovascular magnetic resonance (SCMR) endorsed by the European association for cardiovascular imaging (EACVI). J Cardiovasc Magn Reson. 2017;19(1):75.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"717_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246764","volume":"16","author":"AY Higgins","year":"2021","unstructured":"Higgins AY, Arbune A, Soufer A, et al. Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity. PLoS One. 2021;16(2):e0246764.","journal-title":"PLoS One"},{"issue":"33","key":"717_CR12","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"AL Caforio","year":"2013","unstructured":"Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2013;34(33):2636\u201348 (48a-48d).","journal-title":"Eur Heart J"},{"issue":"1","key":"717_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41569-018-0087-8","volume":"16","author":"E Brakenhielm","year":"2019","unstructured":"Brakenhielm E, Alitalo K. Cardiac lymphatics in health and disease. Nat Rev Cardiol. 2019;16(1):56\u201368.","journal-title":"Nat Rev Cardiol"},{"issue":"18","key":"717_CR14","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u201355.","journal-title":"N Engl J Med"},{"issue":"12","key":"717_CR15","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Zhang L, Zafar A, et al. Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated myocarditis. J Am Coll Cardiol. 2021;77(12):1503\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"717_CR16","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","volume":"29","author":"C Fenioux","year":"2023","unstructured":"Fenioux C, Abbar B, Boussouar S, et al. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med. 2023;29(12):3100\u201310.","journal-title":"Nat Med"},{"issue":"3","key":"717_CR17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1148\/radiol.211765","volume":"303","author":"F Cadour","year":"2022","unstructured":"Cadour F, Cautela J, Rapacchi S, et al. Cardiac MRI features and prognostic value in immune checkpoint inhibitor-induced myocarditis. Radiology. 2022;303(3):512\u201321.","journal-title":"Radiology"},{"issue":"18","key":"717_CR18","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","volume":"41","author":"L Zhang","year":"2020","unstructured":"Zhang L, Awadalla M, Mahmood SS, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733\u201343.","journal-title":"Eur Heart J"},{"issue":"1","key":"717_CR19","volume":"6","author":"BJ Wintersperger","year":"2022","unstructured":"Wintersperger BJ, Calvillo-Arguelles O, Lheureux S, et al. Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated cardiovascular magnetic resonance Lake Louise criteria. Eur Heart J. 2022;6(1):ytab478.","journal-title":"Eur Heart J"},{"issue":"3","key":"717_CR20","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1148\/radiol.2021210814","volume":"301","author":"A Faron","year":"2021","unstructured":"Faron A, Isaak A, Mesropyan N, et al. Cardiac MRI depicts immune checkpoint inhibitor-induced myocarditis: a prospective study. Radiology. 2021;301(3):602\u20139.","journal-title":"Radiology"},{"issue":"11","key":"717_CR21","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.1007\/s00330-022-08844-x","volume":"32","author":"SH Zhao","year":"2022","unstructured":"Zhao SH, Yun H, Chen CZ, et al. The prognostic value of global myocardium strain by CMR-feature tracking in immune checkpoint inhibitor-associated myocarditis. Eur Radiol. 2022;32(11):7657\u201367.","journal-title":"Eur Radiol"},{"issue":"10","key":"717_CR22","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.21037\/qims-22-41","volume":"12","author":"J Liu","year":"2022","unstructured":"Liu J, Cao Y, Zhu K, et al. Early evaluation of subclinical cardiotoxicity in patients with lung cancer receiving immune checkpoint inhibitors by cardiovascular magnetic resonance: a prospective observational study. Quant Imaging Med Surg. 2022;12(10):4771\u201385.","journal-title":"Quant Imaging Med Surg"},{"issue":"11","key":"717_CR23","doi-asserted-by":"publisher","first-page":"8345","DOI":"10.1007\/s00432-023-04782-3","volume":"149","author":"X Tang","year":"2023","unstructured":"Tang X, Li Y, Huang H, et al. Early evaluation of severe immune checkpoint inhibitor-associated myocarditis: a real-world clinical practice. J Cancer Res Clin Oncol. 2023;149(11):8345\u201357.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"717_CR24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/ehf2.14664","volume":"11","author":"Z Li","year":"2024","unstructured":"Li Z, Zhao R, Wang C, et al. Cardiac magnetic resonance-based layer-specific strain in immune checkpoint inhibitor-associated myocarditis. ESC Heart Fail. 2024;11(2):1061\u201375.","journal-title":"ESC Heart Fail"},{"issue":"8","key":"717_CR25","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00392-024-02462-x","volume":"113","author":"M Mirabel","year":"2024","unstructured":"Mirabel M, Eslami A, Thibault C, et al. Adverse myocardial and vascular side effects of immune checkpoint inhibitors: a prospective multimodal cardiovascular assessment. Clin Res Cardiol. 2024;113(8):1263\u201373.","journal-title":"Clin Res Cardiol"},{"issue":"12","key":"717_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0314555","volume":"19","author":"JM Kwan","year":"2024","unstructured":"Kwan JM, Shen M, Akhlaghi N, et al. Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors. PLoS One. 2024;19(12):e0314555.","journal-title":"PLoS One"},{"key":"717_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2024.101581","volume":"56","author":"T Lerchner","year":"2025","unstructured":"Lerchner T, Mincu RI, Buhning F, et al. Cardiac magnetic resonance imaging in patients with suspected myocarditis from immune checkpoint inhibitor therapy - a real-world observational study. IJC Heart & Vasculature. 2025;56:101581.","journal-title":"IJC Heart & Vasculature"},{"issue":"3","key":"717_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010568","volume":"13","author":"A Losurdo","year":"2025","unstructured":"Losurdo A, Panico C, Catalano C, et al. Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events. J Immunother Cancer. 2025;13(3):e010568.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"717_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","volume":"148","author":"LH Lehmann","year":"2023","unstructured":"Lehmann LH, Heckmann MB, Bailly G, et al. Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation. 2023;148(6):473\u201386.","journal-title":"Circulation"},{"issue":"16","key":"717_CR30","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1161\/CIR.0000000000001174","volume":"148","author":"D Addison","year":"2023","unstructured":"Addison D, Neilan TG, Barac A, et al. Cardiovascular imaging in contemporary cardio-oncology: a scientific statement from the American Heart Association. Circulation. 2023;148(16):1271\u201386.","journal-title":"Circulation"},{"key":"717_CR31","doi-asserted-by":"crossref","unstructured":"Charpentier E, Boussouar S, Bretagne M, et al. Comprehensive characterization of cardiac, skeletal and diaphragmatic myotoxicity using CMR in patients with immune checkpoint inhibitor therapy and relation to outcomes. J Cardiovasc Magn Reson. 2024;26.","DOI":"10.1016\/j.jocmr.2024.100680"},{"issue":"24","key":"717_CR32","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"JE Salem","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377\u20139.","journal-title":"N Engl J Med"},{"key":"717_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1527048","volume":"12","author":"S Boussouar","year":"2025","unstructured":"Boussouar S, Charpentier E, Abbar B, et al. Case report: immune checkpoint-inhibitor related myotoxicity monitoring using a comprehensive cardiothoracic MRI approach: insights from a clinical case. Front Cardiovasc Med. 2025;12:1527048.","journal-title":"Front Cardiovasc Med"},{"key":"717_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejca.2022.07.018","volume":"177","author":"J Nowatzke","year":"2022","unstructured":"Nowatzke J, Guedeney P, Palaskas N, et al. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: report from an international registry. Eur J Cancer. 2022;177:197\u2013205.","journal-title":"Eur J Cancer"},{"issue":"41","key":"717_CR35","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"2","key":"717_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(2):80\u201391.","journal-title":"Circulation"},{"issue":"11","key":"717_CR37","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","volume":"6","author":"LH Lehmann","year":"2021","unstructured":"Lehmann LH, Cautela J, Palaskas N, et al. Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review. JAMA Cardiol. 2021;6(11):1329\u201337.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"717_CR38","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s11886-023-01915-5","volume":"25","author":"A Vasbinder","year":"2023","unstructured":"Vasbinder A, Ismail A, Salem JE, Hayek SS. Role of biomarkers in the management of immune-checkpoint inhibitor-related myocarditis. Curr Cardiol Rep. 2023;25(9):959\u201367.","journal-title":"Curr Cardiol Rep"},{"issue":"5","key":"717_CR39","first-page":"689","volume":"4","author":"A Vasbinder","year":"2022","unstructured":"Vasbinder A, Chen Y, Procureur A, et al. Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor-induced myocarditis. JACC: CardioOncology. 2022;4(5):689\u2013700.","journal-title":"JACC: CardioOncology"},{"issue":"2","key":"717_CR40","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.acvd.2021.12.001","volume":"115","author":"S Ederhy","year":"2022","unstructured":"Ederhy S, Devos P, Pinna B, et al. (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis. Arch Cardiovasc Dis. 2022;115(2):114\u20136.","journal-title":"Arch Cardiovasc Dis"},{"issue":"3","key":"717_CR41","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaccao.2025.02.004","volume":"7","author":"G Bailly","year":"2025","unstructured":"Bailly G, Robert-Halabi M, Vion PA, et al. Rechallenge after severe immune checkpoint inhibitor myocarditis: venturing into the unknown. JACC CardioOncol. 2025;7(3):300\u20134.","journal-title":"JACC CardioOncol"},{"issue":"10","key":"717_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003594","volume":"9","author":"S Boughdad","year":"2021","unstructured":"Boughdad S, Latifyan S, Fenwick C, et al. (68)Ga-DOTATOC PET\/CT to detect immune checkpoint inhibitor-related myocarditis. J Immunother Cancer. 2021;9(10):e003594.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"717_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41379-019-0363-0","volume":"33","author":"SN Champion","year":"2020","unstructured":"Champion SN, Stone JR. Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms. Mod Pathol. 2020;33(1):99\u2013108.","journal-title":"Mod Pathol"},{"issue":"2","key":"717_CR44","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.acvd.2024.12.005","volume":"118","author":"JE Salem","year":"2025","unstructured":"Salem JE, Ederhy S, Belin L, et al. Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design. Arch Cardiovasc Dis. 2025;118(2):106\u201315.","journal-title":"Arch Cardiovasc Dis"},{"issue":"3","key":"717_CR45","first-page":"234","volume":"7","author":"YC Chen","year":"2025","unstructured":"Chen YC, Dolladille C, Rao A, et al. Immune checkpoint inhibitor myocarditis and left ventricular systolic dysfunction. JACC: CardioOncology. 2025;7(3):234\u201348.","journal-title":"JACC: CardioOncology"},{"issue":"10","key":"717_CR46","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/ejhf.2265","volume":"23","author":"NL Palaskas","year":"2021","unstructured":"Palaskas NL, Segura A, Lelenwa L, et al. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail. 2021;23(10):1725\u201335.","journal-title":"Eur J Heart Fail"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-025-00717-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-025-00717-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-025-00717-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:02:07Z","timestamp":1768550527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-025-00717-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["717"],"URL":"https:\/\/doi.org\/10.1007\/s11897-025-00717-w","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"JES has received financial supports from Novartis, BeiGene, BMS, Banook Group and holds patents related to the prognostication and treatment of ICI-myotoxicities. AP has received honoraria from Novartis for an educational presentation. PT has received honorarium from BeiGene, Novartis, Amgen, BI, and GE for consultation. Other authors have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}